Management of atrial fibrillation in patients with heart failure

Heart Rhythm

Volumn 4, Issue 3 SUPPL., 2007, Pages

  Stevenson, William G ^a   Tedrow, Usha ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Ablation; Antiarrhythmic drugs; Atrial fibrillation; Heart failure

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; WARFARIN;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; BLEEDING; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; CLINICAL TRIAL; DEFIBRILLATOR; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART TAMPONADE; HUMAN; LONG TERM CARE; LUNG EDEMA; MORTALITY; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QT PROLONGATION; RISK BENEFIT ANALYSIS; SINUS RHYTHM; STROKE; SURGICAL RISK; SURVIVAL RATE; TORSADE DES POINTES; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CARDIOTONIC AGENTS; CARDIOVASCULAR AGENTS; CATHETER ABLATION; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 33847305060     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2006.12.003     Document Type: Article

References (34)

1. Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Gong Y., and Liu P.P. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006) 260-269
2. Parkash R., Maisel W.H., Toca F.M., and Stevenson W.G. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am Heart J 150 (2005) 701-706
3. van Veldhuisen D.J., Aass H., El Allaf D., Dunselman P.H., Gullestad L., Halinen M., Kjekshus J., Ohlsson L., Wedel H., and Wikstrand J. Presence and development of atrial fibrillation in chronic heart failure. Eur J Heart Fail 8 (2006) 539-546
4. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., and Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006) 251-259
5. Olsson L.G., Swedberg K., Ducharme A., Granger C.B., Michelson E.L., McMurray J.J., Puu M., Yusuf S., and Pfeffer M.A. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47 (2006) 1997-2004
6. Verma A., Newman D., Geist M., Greenhut S., Laslop J., DeBellis L., Freeman M.R., and Dorian P. Effects of rhythm regularization and rate control in improving left ventricular function in atrial fibrillation patients undergoing atrioventricular nodal ablation. Can J Cardiol 17 (2001) 437-445
7. Wasmund S.L., Li J.M., Page R.L., Joglar J.A., Kowal R.C., Smith M.L., and Hamdan M.H. Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation 107 (2003) 2011-2015
8. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzey J.Y., Kay G.N., Lowe J.E., Olsson S.B., Prystowsky E.N., Tamargo J.L., Wann S., Smith Jr. S.C., Jacobs A.K., Adams C.D., Anderson J.L., Antman E.M., Hunt S.A., Nishimura R., Ornato J.P., Page R.L., Riegel B., Priori S.G., Blanc J.J., Budaj A., Camm A.J., Dean V., Deckers J.W., Despres C., Dickstein K., Lekakis J., McGregor K., Metra M., Morais J., Osterspey A., and Zamorano J.L. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 114 (2006) e257-e354
9. DiMarco J.P., Flaker G., Waldo A.L., Corley S.D., Greene H.L., Safford R.E., Rosenfeld L.E., Mitrani G., and Nemeth M. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 149 (2005) 650-656
10. Deedwania P.C., Singh B.N., Ellenbogen K., Fisher S., Fletcher R., and Singh S.N. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). Circulation 98 (1998) 2574-2579
11. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., Kober L., Sandoe E., Egstrup K., Agner E., Carlsen J., Videbaek J., Marchant B., and Camm A.J. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341 (1999) 857-865
12. Hagens V.E., Crijns H.J., Van Veldhuisen D.J., Van Den Berg M.P., Rienstra M., Ranchor A.V., Bosker H.A., Kamp O., Tijssen J.G., Veeger N.J., and Van Gelder I.C. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 149 (2005) 1106-1111
13. Corley S.D., Epstein A.E., DiMarco J.P., Domanski M.J., Geller N., Greene H.L., Josephson R.A., Kellen J.C., Klein R.C., Krahn A.D., Mickel M., Mitchell L.B., Nelson J.D., Rosenberg Y., Schron E., Shemanski L., Waldo A.L., and Wyse D.G. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109 (2004) 1509-1513
14. Singh B.N., Singh S.N., Reda D.J., Tang X.C., Lopez B., Harris C.L., Fletcher R.D., Sharma S.C., Atwood J.E., Jacobson A.K., Lewis Jr. H.D., Raisch D.W., and Ezekowitz M.D. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 (2005) 1861-1872
15. Weinfeld M.S., Drazner M.H., Stevenson W.G., and Stevenson L.W. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. J Heart Lung Transplant 19 (2000) 638-643
16. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E., Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri R.M., and Ip J.H. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
17. Verma A., and Natale A. Should atrial fibrillation ablation be considered first-line therapy for some patients?. Circulation 112 (2005) 1214-1222
18. Cheema A., Dong J., Dalal D., Vasamreddy C.R., Marine J.E., Henrikson C.A., Spragg D., Cheng A., Nazarian S., Sinha S., Halperin H., Berger R., and Calkins H. Long-term safety and efficacy of circumferential ablation with pulmonary vein isolation. J Cardiovasc Electrophysiol 17 (2006) 1080-1085
19. Chen M.S., Marrouche N.F., Khaykin Y., Gillinov A.M., Wazni O., Martin D.O., Rossillo A., Verma A., Cummings J., Erciyes D., Saad E., Bhargava M., Bash D., Schweikert R., Burkhardt D., Williams-Andrews M., Perez-Lugones A., Abdul-Karim A., Saliba W., and Natale A. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 43 (2004) 1004-1009
20. Pappone C., Rosanio S., Augello G., Gallus G., Vicedomini G., Mazzone P., Gulletta S., Gugliotta F., Pappone A., Santinelli V., Tortoriello V., Sala S., Zangrillo A., Crescenzi G., Benussi S., and Alfieri O. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 42 (2003) 185-197
21. Verma A., Wazni O.M., Marrouche N.F., Martin D.O., Kilicaslan F., Minor S., Schweikert R.A., Saliba W., Cummings J., Burkhardt J.D., Bhargava M., Belden W.A., Abdul-Karim A., and Natale A. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol 45 (2005) 285-292
22. Hsu L.F., Jais P., Sanders P., Garrigue S., Hocini M., Sacher F., Takahashi Y., Rotter M., Pasquie J.L., Scavee C., Bordachar P., Clementy J., and Haissaguerre M. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351 (2004) 2373-2383
23. Stulak J.M., Dearani J.A., Daly R.C., Zehr K.J., Sundt III T.M., and Schaff H.V. Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg 82 (2006) 494-500
24. Wood M.A., Brown-Mahoney C., Kay G.N., and Ellenbogen K.A. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 101 (2000) 1138-1144
25. Ozcan C., Jahangir A., Friedman P.A., Munger T.M., Packer D.L., Hodge D.O., Hayes D.L., Gersh B.J., Hammill S.C., and Shen W.K. Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. Am J Cardiol 92 (2003) 33-37
26. Vanderheyden M., Goethals M., Anguera I., Nellens P., Andries E., Brugada J., and Brugada P. Hemodynamic deterioration following radiofrequency ablation of the atrioventricular conduction system. Pacing Clin Electrophysiol 20 (1997) 2422-2428
27. Sweeney M.O., and Prinzen F.W. A new paradigm for physiologic ventricular pacing. J Am Coll Cardiol 47 (2006) 282-288
28. Twidale N., Manda V., Holliday R., Boler S., Sparks L., Crain J., and Carrier S. Mitral regurgitation after atrioventricular node catheter ablation for atrial fibrillation and heart failure: acute hemodynamic features. Am Heart J 138 (1999) 1166-1175
29. Tops L.F., Schalij M.J., Holman E.R., van Erven L., van der Wall E.E., and Bax J.J. Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. J Am Coll Cardiol 48 (2006) 1642-1648
30. Kindermann M., Hennen B., Jung J., Geisel J., Bohm M., and Frohlig G. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol 47 (2006) 1927-1937
31. Doshi R.N., Daoud E.G., Fellows C., Turk K., Duran A., Hamdan M.H., and Pires L.A. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 16 (2005) 1160-1165
32. Medina-Ravell V.A., Lankipalli R.S., Yan G.X., Antzelevitch C., Medina-Malpica N.A., Medina-Malpica O.A., Droogan C., and Kowey P.R. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?. Circulation 107 (2003) 740-746
33. Geelen P., Brugada J., Andries E., and Brugada P. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 20 (1997) 343-348
34. Healey J.S., Baranchuk A., Crystal E., Morillo C.A., Garfinkle M., Yusuf S., and Connolly S.J. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839